AstraZeneca and Ionis Pharmaceuticals drug eplontersen, brand name Wainua, failed a Phase 3 test in cardiomyopathy caused by transthyretin amyloidosis. More details will be shared at a medical conference next month, but it appears the RNA therapy’s slim hopes now ride on a subgroup analysis.
The post Phase 3 Failure Keeps AstraZeneca and Ionis Out of a Growing Heart Disease Market appeared first on MedCity News.
